Prot# PR-021: A Multicenter, Randomized, Double-blind, Placebo-controlled, Safety and Tolerability Phase 1/2a Study of Two Dosing Regimens of EUR-1100 for Oral Use, In Subjects With Eosinophilic Esophagitis (EoE)"

Project: Research project

Project Details

StatusFinished
Effective start/end date1/26/12 → 1/26/15

Funding

  • Medpace, Inc. (PR-021 // PR-021)
  • Aptalis Pharma US, Inc. (PR-021 // PR-021)